Cardiovascular Disease News, Treatment Articles | CVD Research Studies

Cardiovascular Disease (CVD)


Apabetalone Gets Breakthrough Tx Designation for MACE Prevention

The FDA has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome.
Next post in Cardiovascular Disease (CVD)